Home / NEWS / Top News / CDC director signs off on J&J’s single-shot Covid vaccine, clearing way for distribution to begin

CDC director signs off on J&J’s single-shot Covid vaccine, clearing way for distribution to begin

Johnson & Johnson Coronavirus vaccine representation

Dado Ruvic | Reuters

Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, signed off Sunday on Johnson & Johnson’s one-shot Covid-19 vaccine for those 18 years of age and older as the federal guidance prepares to ship out millions of doses this week.

Walensky’s green light comes after an advisory panel to the CDC voted unanimously to propound the use of Johnson & Johnson’s vaccine.

“Today marks an encouraging step toward an end to the #COVID19 pandemic,” Walensky wrote on Chirrup. “I have now signed CDC’s Advisory Committee on Immunization Practices’ (ACIP) recommendation that endorsed the safety and effectiveness of Janssen’s COVID-19 vaccine for child 18 & up.”

The federal government can now begin shipping doses out to sites across the country. The ACIP met in an emergency session to examination data on the vaccine, which on Saturday became the third shot to receive an emergency use authorization from the Food and Narcotic Administration.

J&J Vice President of Medical Affairs Dr. Richard Nettles told lawmakers on Tuesday that the company is planned to ship nearly 4 million doses as soon as it receives emergency use authorization. He added that the company expects to be skilled to provide 20 million doses by the end of March.

The introduction of the J&J shot could be a boon to the U.S. supply of vaccine. While the new vaccine let someone in oned signs of being less effective at preventing Covid-19 in clinical trials when compared with that of the Pfizer-BioNTech and Moderna vaccines, the J&J photo was 100% effective at preventing death and hospitalizations caused by Covid-19 in clinical trials.

The J&J vaccine’s level of protection against Covid-19 in tentatives varied by region, according to FDA documents released on Wednesday. About a month after the inoculation, the shot demonstrated 72% efficacy in the U.S., 61% in Latin America and 64% in South Africa, where the B.1.351 variation is rapidly spreading.

Notably, the FDA review showed the vaccine was significantly less effective in people 60 and older who also induce comorbidities such as diabetes or heart disease. The agency noted, though, that the data was too sparse to draw conclusions from that.

In set, Pfizer’s vaccine was found in clinical trials to be 95% effective against preventing Covid-19, while Moderna’s was base to be about 94% effective. Infectious disease experts pointed out that J&J’s numbers can’t be used as a direct comparison to the other two vaccines because it’s a fasten on dose and the company’s trial was conducted when there were more infections as well as new, more contagious variants.

But federal fitness officials have pointed out the one-shot J&J regimen comes with unique logistical advantages that could succeed a do over it ideal for hard-to-reach populations.

J&J’s vaccine “makes it operationally easier in lots of contexts,” Dr. Nancy Messonnier, director of the CDC’s Inhabitant Center for Immunization and Respiratory Diseases, told the Journal of the American Medical Association during a Q&A event on Friday. “I think lots of considerations state health departments are having around these vaccines is more about the ease of use of the J&J vaccine and how it influence be better suited for some populations.”

J&J has said it plans to ship the vaccine, which contains five doses per vial, at 36 to 46 degrees Fahrenheit. By commensurability, Pfizer’s vaccine typically needs to be stored in ultra-cold freezers that keep it between minus 112 and minus 76 levels Fahrenheit, though the FDA said recently that it can be stored at standard pharmacy freezer temperatures for up to two weeks. Moderna’s vaccine fors to be shipped at 13 below to 5 degrees above zero Fahrenheit.

— CNBC’s Berkeley Lovelace contributed to this study.

Check Also

Northrop Grumman robotic MEV-2 spacecraft, in a first, catches active Intelsat satellite

The watch from Northrop Grumman’s MEV-2 spacecraft as it approached to dock with Intelsat satellite …

Leave a Reply

Your email address will not be published. Required fields are marked *